These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25528852)

  • 1. [Osteodeficiency in chronic pancreatitis: ways of correction].
    Babinets' LS; Semenova IV; Borovyk IO
    Lik Sprava; 2014 Nov; (11):134-8. PubMed ID: 25528852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative analysis of programs of complete correction osteogenic in patients with chronic pancreatitis].
    Babinets' LS; Semenova IV; Borovyk IO
    Wiad Lek; 2014; 67(2 Pt 2):282-4. PubMed ID: 25796849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
    Khedr NF; El-Ashmawy NE; El-Bahrawy HA; Haggag AA; El-Abd EE
    Fundam Clin Pharmacol; 2013 Oct; 27(5):526-34. PubMed ID: 22762129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis in men.
    Lems WF; Geusens PP
    N Engl J Med; 2008 Aug; 359(8):868; author reply 869. PubMed ID: 18724402
    [No Abstract]   [Full Text] [Related]  

  • 7. [Differences among bisfosfonates--specificity of risedronate (Actonel)].
    Giljević Z
    Reumatizam; 2008; 55(2):78-80. PubMed ID: 19024283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoporosis treatment: choices and options].
    Reginster JY
    Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
    [No Abstract]   [Full Text] [Related]  

  • 9. [Risedronate for treatment of osteoporosis].
    Hagino H
    Nihon Rinsho; 2009 May; 67(5):948-53. PubMed ID: 19432115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
    Majima T; Komatsu Y; Doi K; Takagi C; Shigemoto M; Fukao A; Morimoto T; Corners J; Nakao K
    J Bone Miner Metab; 2006; 24(2):105-13. PubMed ID: 16502116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis in older people: a tale of two studies (and three treatments).
    Troen BR
    J Am Geriatr Soc; 2006 May; 54(5):853-5. PubMed ID: 16696755
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD; Faber H; Farahmand P; Dorst A
    Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
    Sato S
    Clin Calcium; 2007 Apr; 17(4):600-5. PubMed ID: 17404491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
    Ye Y; Hu SJ
    Bone; 2009 Sep; 45(3):609-10; author reply 611. PubMed ID: 19465167
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evidence of risedronate for treatment of osteoporosis].
    Soen S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():344-7. PubMed ID: 18161128
    [No Abstract]   [Full Text] [Related]  

  • 19. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
    Kishimoto H
    Clin Calcium; 2008 Oct; 18(10):1417-26. PubMed ID: 18830038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.